- Home
- » Tags
- » Teneligliptin
Top View
- Recommendations of the SEC (Endocrinology & Metabolism) Made in Its 55Thmeeting Held on 21.05.2019 at CDSCO HQ New Delhi: Ag
- Summary of Investigation Results Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination Products
- Diabetes Mellitus (1 of 42)
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
- Protocol for Non-Interventional Studies Based on Existing Data TITLE PAGE
- Effect of Teneligliptin Versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: a Real-World Study in Korea
- Recommendations of the SEC (Endocrinology & Metabolism)
- Erratum to “Validity Assessment of Self-Reported Medication Use For
- Pharmaceutical Composition for Preventing Or Treating Diabetes, Containing Zinc Salt, Cyclo-Hispro and Antidiabetic Drug As Active Ingredients
- Clinical Therapeutics/New Technology— Glucose Monitoring and Sensing 2348‑Pub
- A Case Series of Five Hypertensive Type 2 Diabetes Patients Showing
- Journal of Nippon Medical School Vol.85 No.2
- Optimization of a Single HPLC-PDA Method for Quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxa
- Efficacy and Safety of Teneligliptin As Add-On Therapy to Conventional Therapy in Indian Patients with Type 2 Diabetes Mellitus
- Targets and Off-Targets of Kinase Inhibitors in Diabetes
- Data Supplement
- Clinical Diabetes/Therapeutics
- A Study of Effectiveness of Addition of Drug Teneligliptin to Metformin, Glimepiride, Pioglitazone Combination in Type II Diabetic Patients
- Pharmacoeconomic Analysis of Oral Hypoglycaemic Drugs Used In
- Comparison of Efficacy and Safety of Teneligliptin
- (SGLT2) Inhibitors: a Systematic Review and Meta-Analysis
- Complete Dissertation
- 1. Composition Each Tablet Contains Teneligliptin 20 Mg Metformin 500/1000 Mg
- Original Article Cardiovascular Safety of Dipeptidyl Peptidase-4 Inhibitors: Recent Evidence on Heart Failure
- For the Use Only of a Registered Medical Practitioners Or a Hospital Or a Laboratory
- Effect of Teneligliptin Supplementation As Add on Therapy to Metformin In
- Teneligliptin: DPP-4 Inhibitor in the Treatment of Type II Diabetes Mellitus
- Molecular Docking of Fluvastatin and Teneligliptin Targeting AT1R in Hypertension
- Teneligliptin Tablets 20 Mg-Prescribing Information Leaflet-1
- ICMR GUIDELINES for MANAGEMENT of TYPE 2 DIABETES 2018 S.NO CONTENTS PAGE NO. PREAMBLE SECTION 1 : INTRODUCTION 1.1 Definition 1
- Association Between Dipeptidyl Peptidase-4 Inhibitors and Autoimmune Disorders: Data Mining of the Spontaneous Reporting System in Japan
- New Drugs for Type 2 Diabetes: Second-Line Therapy – Science Report
- Assessment of Current Prescribing Pattern and Cost Analysis of Oral Anti- Diabetic Drugs in Elderly Population from Punganur Region of Andhra Pradesh
- I Position of the European Parliament
- (Endocrinology) Meeting Deliberated the Proposals on 05-04-2016 and Recommended the Following
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Overview of Type 2 Diabetes Drugs on the Market
- Association Between Use of Sodium-Glucose Cotransporter 2
- Effects of Teneligliptin on Pdmps and PAI-1 in Patients with Diabetes on Hemodialysis
- Glenmark Becomes the First Company to Launch Remogliflozin + Vildagliptin Fixed Dose Combination, at an Affordable Price for Adults with Type 2 Diabetes in India
- Biocatalyzed Synthesis of Antidiabetic Drugs: a Review
- Title Efficacy and Safety of Teneligliptin Added to Canagliflozin Monotherapy
- Assessment Report
- WO 2017/095725 Al 8 June 2017 (08.06.2017) W P O P C T
- Dr. Subhash Chandra Yadav INTERNATIONAL JOURNAL OF
- Choosing the Best Oral Diabetic Agents in T2 Diabetes Mellitus
- History of Glucose-Lowering Agent Development
- Each Tablet Contains Teneligliptin 20 Mg Metformin 500/1000 Mg Generic
- Identification and Characterization of Antidiabetic And
- Lower Cardiovascular Risk with Diabetic Drugs: a Paradigm Shift
- Possibility of Pharmacokinetic Drug Interaction Between a DPP-4 Inhibitor and a SGLT2 Inhibitor
- WO 2017/198177 Al 23 November 2017 (23.11.2017) W !P O PCT